Zoracopan is a selective complement factor D (CFD) inhibitor. When administered systemically (orally or intravenously), Zoracopan accumulates and is sustained-released in ocular tissues, primarily in the choroid-retinal pigment epithelium (C-RPE) and/or iridociliary body (I-CB).
References:
[1]. Ocular drug depot for complement-mediated disorders. WO2021183555A1 - Ocular drug depot for complement-mediated disorders - Google Patents.
















